BIOLASE, Inc.
BIOL · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $11 | $12 | $10 | $13 |
| % Growth | -6.1% | 14.1% | -24.9% | – |
| Cost of Goods Sold | $6 | $7 | $7 | $10 |
| Gross Profit | $4 | $5 | $3 | $4 |
| % Margin | 40.4% | 39.9% | 32.9% | 26.1% |
| R&D Expenses | $1 | $1 | $1 | $2 |
| G&A Expenses | $1 | $3 | $3 | $3 |
| SG&A Expenses | $4 | $7 | $7 | $7 |
| Sales & Mktg Exp. | $3 | $4 | $3 | $4 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $8 | $8 | $9 |
| Operating Income | -$1 | -$3 | -$5 | -$5 |
| % Margin | -6.4% | -27.9% | -44.7% | -37.6% |
| Other Income/Exp. Net | -$1 | $0 | -$2 | -$0 |
| Pre-Tax Income | -$1 | -$3 | -$6 | -$5 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$1 | -$3 | -$6 | -$5 |
| % Margin | -13.2% | -24.2% | -64% | -39.5% |
| EPS | -0.04 | -0.084 | -0.36 | -1.76 |
| % Growth | 52.7% | 76.7% | 79.5% | – |
| EPS Diluted | -0.04 | -0.084 | -0.36 | -1.76 |
| Weighted Avg Shares Out | 36 | 33 | 18 | 3 |
| Weighted Avg Shares Out Dil | 36 | 33 | 18 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $0 | $1 | $1 |
| EBITDA | -$0 | -$2 | -$5 | -$4 |
| % Margin | -1.5% | -13.3% | -51.2% | -30.2% |